5 Stocks Making Waves on Wall Street: The Trade Desk, SoundHound AI, Eli Lilly, Block, and CrowdStrike

The US stock market saw a mixed performance, with the Nasdaq gaining 0.35% and the S&P 500 falling 0.08%. The Trade Desk's stock fell 1.4% to $88.33, while SoundHound AI's stock rose 13.9% to $12.21. Eli Lilly's stock plummeted 14.14% to $640.86, and Block's stock rose 0.95% to $76.85. CrowdStrike's stock declined 5.91% to $425.

The US stock market experienced a mixed performance on Thursday, July 2, 2025, with the Nasdaq gaining 0.35% and the S&P 500 falling 0.08%. The Trade Desk's stock fell 1.4% to $88.33, while SoundHound AI's stock rose 13.9% to $12.21. Eli Lilly's stock plummeted 14.14% to $640.86, and Block's stock rose 0.95% to $76.85. CrowdStrike's stock declined 5.91% to $425.

The day's performance was influenced by geopolitical uncertainties and corporate earnings reports. The S&P 500 and Nasdaq 100 indices showed modest gains following a period of volatility triggered by recent geopolitical tensions and shifts in fiscal policy [1]. The gains were partially driven by expectations of potential easing in US monetary policy, as investors anticipate interest rate cuts by the Federal Reserve [1].

The Trade Desk (TTD) stock closed at $86.08, marking a -1.01% move from the prior day. This change was narrower than the S&P 500's 1.6% loss on the day. Prior to today's trading, shares of the digital-advertising platform operator had gained 16.87% outpaced the Computer and Technology sector's gain of 4.45% and the S&P 500's gain of 2.25% [2].

Eli Lilly and Company (LLY) experienced a dramatic decline in its stock price, falling by more than 14% in early trading. The significant sell-off was triggered by the release of disappointing clinical trial data for its oral weight-loss pill, orforglipron. This setback overshadowed an otherwise robust second-quarter earnings report and an optimistic increased full-year outlook [3].

The market's sharp reaction underscores the high stakes in the race for effective and convenient weight-loss treatments. While Eli Lilly's existing injectable obesity medicine, Zepbound (tirzepatide), continues to demonstrate strong growth, the less-than-stellar performance of its oral counterpart has raised questions about the company's ability to dominate all facets of this lucrative market [3].

Looking ahead, investors will be attentive to upcoming economic data releases, including employment figures and inflation reports, which could provide further insight into the trajectory of the global economy. While current indicators suggest cautious optimism, the interplay between domestic policies and global economic conditions will continue to shape market sentiment [1].

References:
[1] https://tradersunion.com/news/financial-news/show/423028-stock-market-recap-sp-500-nasdaq-100-gain-about-1/
[2] https://www.nasdaq.com/articles/trade-desk-ttd-stock-moves-101-what-you-should-know
[3] https://markets.financialcontent.com/wral/article/marketminute-2025-8-7-eli-lilly-shares-tumble-after-disappointing-weight-loss-pill-data